Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epanova for maintenance of remission in Crohn's Disease
NCT00613197Phase 3Completed
- Sponsor
- Tillotts Pharma AG
- Start
- Jan 2003
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Epanova with Placebo (2 arms). Primary endpoint: Time to clinical relapse at 52 weeks. Started Jan 2003; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00613197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00613197.